PSYCH up2date, Table of Contents PSYCH up2date 2014; 8(06): 365-376DOI: 10.1055/s-0034-1387369 Schizophrenien und andere psychotische Störungen Depression bei Schizophrenie Lena Grüber , Peter Falkai , Alkomiet Hasan Recommend Article Abstract Buy Article All articles of this category Full Text References Literatur 1 Birchwood M, Iqbal Z, Upthegrove R. Psychological pathways to depression in schizophrenia: studies in acute psychosis, post psychotic depression and auditory hallucinations. Eur Arch Psychiatry Clin Neurosci 2005; 255: 202-212 2 Maurer K, Trendler G, Schmidt M. et al. Schizophrenie und Depression. Nervenarzt 2006; 77: 809-822 3 Van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468: 203-212 4 Van Os J, Kapur S. Schizophrenia. Lancet 2009; 374: 635-645 5 Mauri MC, Bitetto A, Fabiano L. et al. Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23: 43-54 6 Anderson G, Berk M, Dodd S. et al. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course, and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 1-4 7 Hasan A, Falkai P, Wobrock T. et al. WFSBP Task force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term-treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013; 14: 2-44 8 Sönmez N, Romm KL, Andreasssen OA. et al. Depressive symptoms in first episode psychosis: a one-year follow-up study. BMC Psychiatry 2013; 13: 106 9 Hasan A, Falkai P, Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13: 318-378 10 APA Practice Guideline for the Treatment of Patients with Schizophrenia Second Edition, Work Group on Schizophrenia. 2004. 11 Dilling H, Mombour W, Schmidt MH. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V(F): Klinisch-diagnostische Leitlinien. 8.. Aufl. Bern: Huber; 2011 12 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM 5. 5th. ed., 2nd printing Juni 2013. www.PsychiatryOnline.org 13 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Hrsg. S3-Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 – Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff; 2006 14 Lako IM, Bruggeman R, Knegtering H. et al. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J Affect Disord 2012; 140: 38-47 15 Möller HJ. Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues. World J Biol Psychiatry 2005; 6: 247-263 16 Scholes B, Martin CR. Measuring depression in schizophrenia with questionnaires. J Psychiatr Ment Health Nurs 2013; 20: 17-22 17 Drake RJ, Pickles A, Bentall RP. et al. The evolution of insight, paranoia, and depression during early schizophrenia. Psychol Med 2004; 34: 285-292 18 Challis S, Nielssen O, Harris A. et al. Systematic meta-analysis of the risk factors for deliberate self-harm before and after treatment for first-episode psychosis. Acta Psychiatr Scand 2013; 127: 442-454 19 Leucht S, Heres S, Kissling W. et al. Pharmacological treatment of schizophrenia. Fortschr Neurol Psychiatr 2013; 81: e1-13 20 Leucht S, Corves C, Arbter D. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41 21 Leucht S, Arbter D, Engel RR. et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009; 14: 429-447 22 Kjelby E, Jørgensen HA, Kroken RA. et al. Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiatry 2011; 11: 145 23 Rybakowski JK, Vansteelandt K, Szafranski T. et al. EUFEST Study Group. Treatment of depression in first episode of schizophrenia: results from EUFEST. Eur Neuropsychopharmacol 2012; 22: 875-882 24 Whitehead C, Moss S, Cardno A. et al. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev. 2002; 2: CD002305 25 Whitehead C, Moss S, Cardno A. et al. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med 2003; 33: 589-599 26 Englisch S, Morgen K, Meyer-Lindenberg A. et al. Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature. Clin Neuropharmacol 2013; 36: 203-215 27 Terevnikov V, Stenberg JH, Tiihonen J. et al. Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. Hum Psychopharmacol 2011; 26: 188-193 28 Buchanan RW, Kreyenbuhl J, Kelly DL. et al. Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71-93
